Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891446231> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2891446231 abstract "e18506 Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, has demonstrated superior clinical activity versus standard of care (SOC; intensive chemotherapy), including clinically meaningful improvement in overall survival (OS), high rates of complete remission (CR) and stem cell transplantation (SCT), and favorable patient-reported outcomes for R/R ALL in the phase 3 INO-VATE trial. Quality of life is an important consideration for R/R ALL patients in both short- and long-term survival. This study aimed to estimate mean overall survival adjusted for QoL (QALY) for patients treated with InO v SOC. Methods: A Markov model was developed with five health states - No CR, CR, post-SCT, progression, and death. Transition probabilities between health states and mortality rates were based on the InO-VATE trial. These rates were extrapolated to a lifetime horizon using parametric survival curves fitted to available OS data, and published literature for survival after SCT. Utilities (QoL valuations) for each health state were based on the patient-reported EQ-5D scores collected in the InO-VATE trial and a literature review. Adverse events experienced during and after treatments, including as a result of subsequent SCT, were taken into account in overall QoL. Outcomes were discounted at 1.5% and half-cycle corrected. Results: The estimated mean LY and QALY in each health state for InO and SOC and their differences are shown in Table. Most gains in LY and QALY for InO over SOC were from Post-SCT. Conclusions: This analysis taking into account both quantity and quality of life estimates InO offers an average of nearly 2 more years of QALY compared to SOC in R/R ALL, based on higher CR and SCT rates and better QOL. This is mainly driven by long-term gains of SCT. This can help inform patients, physicians and payers in decision making. [Table: see text]" @default.
- W2891446231 created "2018-09-27" @default.
- W2891446231 creator A5019430843 @default.
- W2891446231 creator A5033501287 @default.
- W2891446231 creator A5039926945 @default.
- W2891446231 creator A5049530860 @default.
- W2891446231 creator A5059506644 @default.
- W2891446231 creator A5072480385 @default.
- W2891446231 date "2017-05-20" @default.
- W2891446231 modified "2023-09-27" @default.
- W2891446231 title "Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL)." @default.
- W2891446231 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18506" @default.
- W2891446231 hasPublicationYear "2017" @default.
- W2891446231 type Work @default.
- W2891446231 sameAs 2891446231 @default.
- W2891446231 citedByCount "4" @default.
- W2891446231 countsByYear W28914462312017 @default.
- W2891446231 countsByYear W28914462312018 @default.
- W2891446231 crossrefType "journal-article" @default.
- W2891446231 hasAuthorship W2891446231A5019430843 @default.
- W2891446231 hasAuthorship W2891446231A5033501287 @default.
- W2891446231 hasAuthorship W2891446231A5039926945 @default.
- W2891446231 hasAuthorship W2891446231A5049530860 @default.
- W2891446231 hasAuthorship W2891446231A5059506644 @default.
- W2891446231 hasAuthorship W2891446231A5072480385 @default.
- W2891446231 hasConcept C112930515 @default.
- W2891446231 hasConcept C121332964 @default.
- W2891446231 hasConcept C126322002 @default.
- W2891446231 hasConcept C142424586 @default.
- W2891446231 hasConcept C143998085 @default.
- W2891446231 hasConcept C187212893 @default.
- W2891446231 hasConcept C2778461978 @default.
- W2891446231 hasConcept C2909962599 @default.
- W2891446231 hasConcept C2993769353 @default.
- W2891446231 hasConcept C3019080777 @default.
- W2891446231 hasConcept C64332521 @default.
- W2891446231 hasConcept C71924100 @default.
- W2891446231 hasConcept C87355193 @default.
- W2891446231 hasConceptScore W2891446231C112930515 @default.
- W2891446231 hasConceptScore W2891446231C121332964 @default.
- W2891446231 hasConceptScore W2891446231C126322002 @default.
- W2891446231 hasConceptScore W2891446231C142424586 @default.
- W2891446231 hasConceptScore W2891446231C143998085 @default.
- W2891446231 hasConceptScore W2891446231C187212893 @default.
- W2891446231 hasConceptScore W2891446231C2778461978 @default.
- W2891446231 hasConceptScore W2891446231C2909962599 @default.
- W2891446231 hasConceptScore W2891446231C2993769353 @default.
- W2891446231 hasConceptScore W2891446231C3019080777 @default.
- W2891446231 hasConceptScore W2891446231C64332521 @default.
- W2891446231 hasConceptScore W2891446231C71924100 @default.
- W2891446231 hasConceptScore W2891446231C87355193 @default.
- W2891446231 hasLocation W28914462311 @default.
- W2891446231 hasOpenAccess W2891446231 @default.
- W2891446231 hasPrimaryLocation W28914462311 @default.
- W2891446231 hasRelatedWork W2431308767 @default.
- W2891446231 hasRelatedWork W2523326396 @default.
- W2891446231 hasRelatedWork W2604901999 @default.
- W2891446231 hasRelatedWork W2735686643 @default.
- W2891446231 hasRelatedWork W2762071151 @default.
- W2891446231 hasRelatedWork W2765295561 @default.
- W2891446231 hasRelatedWork W2887220120 @default.
- W2891446231 hasRelatedWork W2890700631 @default.
- W2891446231 hasRelatedWork W2906433309 @default.
- W2891446231 hasRelatedWork W2949284331 @default.
- W2891446231 hasRelatedWork W2951450900 @default.
- W2891446231 hasRelatedWork W2954404383 @default.
- W2891446231 hasRelatedWork W2970311002 @default.
- W2891446231 hasRelatedWork W2971296434 @default.
- W2891446231 hasRelatedWork W2972590146 @default.
- W2891446231 hasRelatedWork W2981814394 @default.
- W2891446231 hasRelatedWork W3023621931 @default.
- W2891446231 hasRelatedWork W3033416356 @default.
- W2891446231 hasRelatedWork W3112684887 @default.
- W2891446231 hasRelatedWork W2766375908 @default.
- W2891446231 isParatext "false" @default.
- W2891446231 isRetracted "false" @default.
- W2891446231 magId "2891446231" @default.
- W2891446231 workType "article" @default.